Multiple facets of cAMP signalling and physiological impact: CAMP compartmentalization in the lung

Pharmaceuticals

Volumn 5, Issue 12, 2012, Pages 1291-1331

  Oldenburger, Anouk ^a,b   Maarsingh, Harm ^a,b   Schmidt, Martina ^a,b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

A kinase anchoring proteins (AKAPs); Barrier function; cAMP compartmentalization; COPD; Epac

Indexed keywords

ADENYLATE CYCLASE; ALPHA CATENIN; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA CATENIN; BIGLYCAN; CLAUDIN; COLLAGEN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN; CYCLIC AMP PHOSPHODIESTERASE; DECORIN; FENOTEROL; FORMOTEROL; FORSKOLIN; G PROTEIN COUPLED RECEPTOR; INDACATEROL; INTERLEUKIN 8; IQ MOTIF CONTAINING GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN 1; MYOSIN IIA; MYOSIN IIB; OCCLUDIN; PHOSPHODIESTERASE IV; PROTEIN ZO1; PROTEIN ZO2; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA; ROFLUMILAST; ROLIPRAM; SALBUTAMOL; UNINDEXED DRUG;

BRONCHUS MUCOSA; CELL COMPARTMENTALIZATION; CELL INTERACTION; CELL JUNCTION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE MARKER; DRUG EFFICACY; DRUG MECHANISM; EMPHYSEMA; EPITHELIUM CELL; HUMAN; INTRACELLULAR SIGNALING; LUNG DISEASE; LUNG FIBROBLAST; LUNG FUNCTION; MOLECULAR INTERACTION; NONHUMAN; PATHOGENESIS; POLLUTION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SMOKING; VASCULAR ENDOTHELIUM;

EID: 84871059795     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph5121291     Document Type: Review

References (320)

1. Beavo, J.A.; Brunton, L.L. Cyclic nucleotide research -- still expanding after half a century. Nat. Rev. Mol. Cell Biol. 2002, 3, 710-718.
2. Sayner, S.L. Emerging themes of cAMP regulation of the pulmonary endothelial barrier. Am. J. Physiol. Lung Cell Mol. Physiol. 2011, 300, L667-L678.
3. Conti, M.; Beavo, J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu. Rev. Biochem. 2007, 76, 481-511.
4. Houslay, M.D. Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. Trends Biochem. Sci. 2010, 35, 91-100.
5. McCahill, A.C.; Huston, E.; Li, X.; Houslay, M.D. PDE4 associates with different scaffolding proteins: modulating interactions for certain diseases. Handb. Exp. Pharmacol 2008, 186, 125-166.
6. Hanoune, J.; Defer, N Regulation and role of adenylyl cyclase isoforms. Annu. Rev. Pharmacol Toxicol. 2001, 41, 145-174.
7. Patel, H.H.; Murray, F.; Insel, P.A. G-protein-coupled receptor-signaling components in membrane raft and caveolae microdomains. Handb. Exp. Pharmacol 2008, 167-184.
8. Patel, H.H.; Murray, F.; Insel, P.A. Caveolae as organizers of pharmacologically relevant signal transduction molecules. Annu. Rev. Pharmacol Toxicol. 2008, 48, 359-391.
9. Zaccolo, M.; Pozzan, T. Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes. Science 2002, 295, 1711-1715.
10. Di Benedetto, G.; Zoccarato, A.; Lissandron, V.; Terrin, A.; Li, X.; Houslay, M.D.; Baillie, G.S.; Zaccolo, M. Protein kinase A type I and type II define distinct intracellular signaling compartments. Circ. Res. 2008, 103, 836-844.
11. Zaccolo, M. cAMP signal transduction in the heart: understanding spatial control for the development of novel therapeutic strategies. Br. J. Pharmacol. 2009, 158, 50-60.
12. Zaccolo, M. Spatial control of cAMP signalling in health and disease. Curr. Opin. Pharmacol 2011, 11, 649-655.
13. Stangherlin, A.; Zaccolo, M. Phosphodiesterases and subcellular compartmentalized cAMP signaling in the cardiovascular system. Am. J. Physiol Heart Circ. Physiol. 2012, 302, H379-H390.
14. Beene, D.L.; Scott, J.D. A-kinase anchoring proteins take shape. Curr. Opin. Cell Biol. 2007, 19, 192-198.
15. Skroblin, P.; Grossmann, S.; Schafer, G.; Rosenthal, W.; Klussmann, E. Mechanisms of protein kinase A anchoring. Int. Rev. Cell Mol. Biol. 2010, 283, 235-330.
16. Wong, W.; Scott, J.D. AKAP signalling complexes: focal points in space and time. Nat. Rev. Mol. Cell Biol. 2004, 5, 959-970.
17. Tröger, J.; Moutty, M.C.; Skroblin, P.; Klussmann, E. A-kinase anchoring proteins as potential drug targets. Br. J. Pharmacol. 2012, 166, 420-433.
18. Nikolaev, V.O.; Moshkov, A.; Lyon, A.R.; Miragoli, M.; Novak, P.; Paur, H.; Lohse, M.J.; Korchev, Y.E.; Harding, S.E.; Gorelik, J. Beta2-adrenergic receptor redistribution in heart failure changes cAMP compartmentation. Science 2010, 327, 1653-1657.
19. Ostroveanu, A.; van der Zee, E.; Eisel, U.L.; Schmidt, M.; Nijholt, I.M. Exchange protein directly activated by cyclic AMP2 (Epac2) plays a specific and time-limited role in memory retrieval. Hippocampus 2010, 20, 1018-1026.
20. Aye, T.-T.; Soni, S.; van Veen, T.A.B.; van der Heyden, M.A.G.; Cappadona, S.; Varro, A.; de Weger, R.A.; de Jonge, N.; Vos, M.A.; Heck, A.J.R.; Scholten, A. Reorganized PKA-AKAP associations in the failing human heart. J. Mol. Cell. Cardiol. 2012, 52, 511-518.
21. Kovanich, D.; van der Heyden, M.A.; Aye, T.T.; van Veen, T.A.; Heck, A.J.; Scholten, A. Sphingosine kinase interacting proteins is an A-kinase anchroing protein specific for type I cAMP-dependent protein kinase. Chembiochem. 2010, 3, 963-971.
22. Noda, K.; Zhang, J.; Fukuhara, S.; Kunimotot, S.; Yoshimura, M.; Mochizuki, N. Vascular endothelial-cadherin stabilizes at cell-cell junctions by anchoring to circumferential actin bundles through a- and b-catenins in cyclic AMP-Epac1-Rap1 signal-activated endothelial cells. Mol. Cell. Biol. 2010, 21, 584-596.
23. Hogg, J.C.; Chu, F.; Utokaparch, S.; Woods, R.; Elliott, W.M.; Buzatu, L.; Cherniack, R.M.; Rogers, R.M.; Sciurba, F.C.; Coxson, H.O.; Pare, P.D. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004, 350, 2645-2653.
24. Hogg, J.C.; Timens, W. The pathology of chronic obstructive pulmonary disease. Annu. Rev. Pathol. 2009, 4, 435-459.
25. Barnes, P.J. Immunology of asthma and chronic obstructive pulmonary disease. Nat. Rev. Immunol. 2008, 8, 183-192.
26. van den Berge, M.; ten Hacken, N.H.; Cohen, J.; Douma, W.R.; Postma, D.S. Small airway disease in asthma and COPD: clinical implications. Chest 2011, 139, 412-423.
27. Rogers, D.F.; Barnes, P.J. Trends in clinical practice: Treatment of airway mucus hypersecretion. Ann. Med. 2006, 38, 116-125.
28. Lai, H.; Rogers, D.F. New pharmacotherapy for airway mucus hypersecretion in asthma and COPD: Targeting intracellular signaling pathways. J. Aerosol. Med. Pulm. Drug Deliv. 2010, 23, 219-231.
29. Shaykhiev, R.; Otaki, F.; Bonsu, P.; Dang, D.T.; Teater, M.; Strulovici-Barel, Y.; Salit, J.; Harvey, B.G.; Crystal, R.G. Cigarette smoking reprograms apical junctional complex molecular architecture in the human airway epithelium in vivo. Cell. Mol. Life Sci. 2011, 68, 877-892.
30. Lai, H.Y.; Rogers, D.F. Mucus hypersecretion in asthma: intracellular signalling pathways as targets for pharmacotherapy. Curr. Opin. Allergy Clin. Immunol. 2010, 10, 67-76.
31. Heijink, I.H.; Brandenburg, S.M.; Postma, D.S.; van Oosterhout, A.J.M. Cigarette smoke impairs airway epithelial barrier function and cell-cell contact recovery. Eur. Respir. J. 2012, 39, 419-428.
32. Lapperre, T.S.; Sont, J.K.; van Schadewijk, A.; Gosman, M.M.E.; Postma, D.S.; Bajema, I.M.; Timens, W.; Maua, T.; Hiemstra, P.S.; and the GLUCOLD Study group. Smoking cessation and bronchial epithelial remodelling in COPD: a cross-sectional study. Respir. Res. 2007, 8, 85.
33. Voynow, J.A.; Rubin, B.K. Mucins, mucus, and sputum. Chest 2009, 135, 505-512.
34. Hurst, J.R.; Vestbo, J.; Anzueto, A.; Locantore, N.; Mullerova, H.; Tal-Singer, R.; Miller, B.; Lomas, D.A.; Agusti, A.; Macnee, W.; Calverley, P.; Rennard, S.; Wouters, E.F.; Wedzicha, J.A. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 2010, 363, 1128-1138.
35. Hopkins, A.L.; Groom, C.R. The druggable genome. Nat. Rev. Drug Discov. 2002, 1, 727-730.
36. Pierce, K.L.; Premont, R.T.; Lefkowitz, R.J. Seven-transmembrane receptors. Nat. Rev. Mol. Cell Biol. 2002, 3, 639-650.
37. Cooper, P.R.; Kurten, R.C.; Zhang, J.; Nicholls, D.J.; Dainty, I.A.; Panettieri, R.A. Formoterol and salmeterol induce a similar degree of beta2-adrenoceptor tolerance in human small airways but via different mechanisms. Br. J. Pharmacol. 2011, 163, 521-532.
38. Penn, R.B. Embracing emerging paradigms of G protein-coupled receptor agonism and signaling to address airway smooth muscle pathobiology in asthma. Naunyn Schmiedebergs Arch. Pharmacol. 2008, 378, 149-169.
39. Bateman, E.D.; Hurd, S.S.; Barnes, P.J.; Bousquet, J.; Drazen, J.M.; FitzGerald, M.; Gibson, P.; Ohta, K.; O'Byrne, P.; Pedersen, S.E.; Pizzichini, E.; Sullivan, S.D.; Wenzel, S.E.; Zar, H.J. Global strategy for asthma management and prevention: GINA executive summary. Eur. Respir. J. 2008, 31, 143-178.
40. Penn, R.B. Agonizing over agonism: should asthmatics turn their beta-receptors on or off? Proc. Natl. Acad. Sci. USA 2009, 106, 2095-2096.
41. Yan, H.; Deshpande, D.A.; Misior, A.M.; Miles, M.C.; Saxena, H.; Riemer, E.C.; Pascual, R.M.; Panettieri, R.A.; Penn, R.B. Anti-mitogenic effects of {beta}-agonists and PGE2 on airway smooth muscle are PKA dependent. FASEB J. 2011, 25, 389-397.
42. Bauman, K.A.; Wettlaufer, S.H.; Okunishi, K.; Vannella, K.M.; Stoolman, J.S.; Huang, S.K.; Courey, A.J.; White, E.S.; Hogaboam, C.M.; Simon, R.H.; Toews, G.B.; Sisson, T.H.; Moore, B.B.; Peters-Golden, M. The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice. J. Clin. Invest. 2010, 120, 1950-1960.
43. Huang, S.K.; Fisher, A.S.; Scruggs, A.M.; White, E.S.; Hogaboam, C.M.; Richardson, B.C.; Peters-Golden, M. Hypermethylation of PTGER2 confers prostaglandin E2 resistance in fibrotic fibroblasts from humans and mice. Am. J. Pathol. 2010, 177, 2245-2255.
44. Stumm, C.L.; Wettlaufer, S.H.; Jancar, S.; Peters-Golden, M. Airway remodeling in murine asthma correlates with a defect in PGE2 synthesis by lung fibroblasts. Am. J. Physiol Lung Cell Mol. Physiol. 2011, 301, L636-L644.
45. Sears, M.R. Safe use of long-acting b-agonists: what have we learnt? Expert. Opin. Drug. Saf. 2012, 10, 767-778.
46. Bos, J.L. Epac: a new cAMP target and new avenues in cAMP research. Nat. Rev. Mol. Cell. Biol. 2003, 4, 733-738.
47. Gloerich, M.; Bos, J.L. Epac: defining a new mechanism for cAMP action. Annu. Rev. Pharmacol.Toxicol. 2010, 50, 355-375.
48. Whalen, E.J.; Rajagopal, S.; Lefkowitz, R.J. Therapeutic potential of beta-arrestin- and G protein-biased agonists. Trends Mol. Med. 2011, 17, 126-139.
49. Rajagopal, S.; Rajagopal, K.; Lefkowitz, R.J. Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev. Drug Discov. 2010, 9, 373-386.
50. Reiter, E.; Ahn, S.; Shukla, A.K.; Lefkowitz, R.J. Molecular mechanisms of b-arrestin-biased agonism at seven-transmembrane receptors. Annu. Rev. Pharmacol. Toxicol. 2012, 52, 179-197.
51. Calebiro, D.; Nikolaev, V.O.; Gagliani, M.C.; de, F.T.; Dees, C.; Tacchetti, C.; Persani, L.; Lohse, M.J. Persistent cAMP-signals triggered by internalized G-protein-coupled receptors. PLoS. Biol. 2009, 7, 1-8
52. Ferrandon, S.; Feinstein, T.N.; Castro, M.; Wang, B.; Bouley, R.; Potts, J.T.; Gardella, T.J.; Vilardaga, J.-P. Sustained cyclic AMP production by parathroid hormone receptor endocytosis. Nat. Chem. Biol. 2009, 5, 734-742.
53. Calebiro, D.; Nikolaev, V.O.; Lohse, M.J. Imaging of persistent cAMP signaling by internalized G protein-coupled receptors. J. Mol. Endocrinol. 2010, 45, 1-8.
54. Murphy, J.E.; Padilla, B.E.; Hasdemir, B.; Cottrell, G.S.; Bunnett, N.W. Endosomes: a legitimate platform for the signaling train. Proc. Natl. Acad. Sci. USA 2009, 106, 17615-17622.
55. Platta, H.W.; Stenmark, H. Endocytosis and signaling. Curr. Opin. Cell Biol. 2011, 23, 393-403.
56. Puthenveedu, M.A.; Lauffer, B.; Temkin, P.; Vistein, R.; Carlton, P.; Thorn, K.; Taunton, J.; Weiner, O.D.; Parton, R.G.; von Zastrow, M. Sequence-dependent sorting of recycling proteins by actin-stabilized endosomal microdomains. Cell 2010, 143, 761-773.
57. Kendall, R.T.; Strungs, E.G.; Rachidi, S.M.; Lee, M.-H.; El-Shewy, H.M.; Luttrell, D.K.; Janech, M.G.; Luttrell, L.M. The b-arrestin pathway-selective type 1A angiotensin receptor (AT1a) agonist [Sar1, IL4, Ile8] angiotensin II regulates a robust G protein-independent signaling network. J. Biol. Chem. 2011, 286, 19880-19891.
58. Walters, R.W.; Shukla, A.K.; Kovacs, J.J.; Violin, J.D.; DeWire, S.M.; Lam, C.M.; Chen, J.R.; Muehlbauer, M.J.; Whalen, E.J.; Lefkowitz, R.J. b-arrestin 1 mediates nicotinic acid-induced flushing, but not its antilipolytic effects, in mice. J. Clin. Invest. 2009, 119, 1312-1321.
59. Rajagopal, S.; Ahn, S.; Gowen-MacDonald, W.; Lam, C.M.; DeWire, S.M.; Violin, J.D.; Lefkowitz, R.J. Quantifying ligand bias at seven-transmembrane receptors. Mol. Pharmacol. 2011, 80, 367-377.
60. Nguyen, L.P.; Lin, R.; Parra, S.; Omoluabi, O.; Hanania, N.A.; Tuvim, M.J.; Knoll, B.J.; Dickey, B.F.; Bond, R.A. Beta2-adrenoceptor signaling is required for the development of an asthma phenotype in a murine model. Proc. Natl. Acad. Sci. USA 2009, 106, 2435-2440.
61. Billington, C.K.; Hall, I.P. Novel cyclic AMP Signalling Paradigms: Therapeutic Implications for Airway Disease. Br. J. Pharmacol. 2011, 166, 401-410.
62. Walker, J.K.; Penn, R.B.; Hanania, N.A.; Dickey, B.F.; Bond, R.A. New perspectives regarding beta(2) -adrenoceptor ligands in the treatment of asthma. Br. J. Pharmacol. 2011, 163, 18-28.
63. Lovgren, A.K.; Kovacs, J.J.; Xie, T.; Potts, E.N.; Li, Y.; Foster, W.M.; Liang, J.; Meltzer, E.B.; Jiang, D.; Lefkowitz, R.J.; Noble, P.W. beta-arrestin deficiency protects against pulmonary fibrosis in mice and prevents fibroblast invasion of extracellular matrix. Sci. Transl. Med. 2011, 3, 74ra23.
64. Manson, M.E.; Corey, D.A.; White, N.M.; Kelley, T.J. cAMP-mediated regulation of cholesterol accumulation in cystic fibrosis and Niemann-Pick type C cells. Am. J. Physiol. Lung Cell Mol. Physiol. 2008, 295, L809-L819.
65. Li, J.; Ghio, A.J.; Cho, S.H.; Brinckerhoff, C.E.; Simon, S.A.; Liedtke, W. Diesel exhaust particles activate the matrix-metalloproteinase-1 gene in human bronchial epithelia in a beta- arrestin-dependent manner via activation of RAS. Environ. Health Perspect. 2009, 117, 400-409.
66. Nobles, K.N.; Xiao, K.; Ahn, S.; Shukla, A.K.; Lam, C.M.; Rajagopal, S.; Strachan, R.T.; Huang, T.Y.; Bressler, E.A.; Hara, M.R.; Shenoy, S.K.; Gygi, S.P.; Lefkowitz, R.J. Distinct phosphorylation sites on the b(2)-adrenergic receptor establish a barcode that encodes differential functions of b-arrestin. Sci. Signal. 2011, 4, ra51.
67. Khasai, A.W.; Xiao, K.; Rajagopal, S.; Ahn, S.; Shukla, A.K.; Sun, J.; Oas, T.G.; Lefkowitz, R.J. Multiple ligand-specific conformations of the b2-adrenergic receptor. Nat. Chem. Biol. 2011, 7, 692-700.
68. Xiao, K.; Sun, J.; Kim, J.; Rajagopal, S.; Zhai, B.; Villen, J.; Haas, W.; Kovacs, J.J.; Shukla, A.K.; Hara, M.R.; Hernandez, M.; Lachmann, A.; Zhao, S.; Lin, Y.; Cheng, Y.; Mizuno, K.; Maáyan, A.; Gygi, S.P.; Lefkowitz, R.J. Global phosphorylation analysis of b-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc. Natl. Acad. Sci. US A 2010, 107, 15299-15304.
69. Berthouze, M.; Venkataramanan, V.; Li, Y.; Shenoy, S.K. The deubiquitinases USP33 and USP20 coordinate b2 adrenergic receptor recycling and resensitization. EMBO J. 2009, 28, 1684-1696.
70. Shenoy, S.K.; Modi, A.S.; Shukla, A.K.; Xiao, K.; Berthouze, M.; Ahn, S.; Wilkinson, K.D.; Miller, W.E.; Lefkowitz, R.J. b-Arrestin-dependent signaling and trafficking of 7-transmembrane receptor is reciprocally regulated by the deubititinase USP33 and the E3 ligase Mdm2. Proc. Natl. Acad. Sci. USA 2009, 106, 6650-6655.
71. Billington, C.K.; Hall, I.P. Real time analysis of beta(2)-adrenoceptor-mediated signaling kinetics in human primary airway smooth muscle cells reveals both ligand and dose dependent differences. Respir. Res. 2011, 12, 89.
72. Lamyel, F.; Warnken-Uhlich, M.; Seemann, W.K.; Mohr, K.; Kostenis, E.; Ahmedat, A.S.; Smit, M.; Gosens, R.; Meurs, H.; Miller-Larsson, A.; Racke, K. The beta2-subtype of adrenoceptors mediates inhibition of pro-fibrotic events in human lung fibroblasts. Naunyn Schmiedebergs Arch. Pharmacol. 2011, 384, 133-145.
73. Giembycz, M.A.; Newton, R. Beyond the dogma: novel beta2-adrenoceptor signalling in the airways. Eur. Respir. J. 2006, 27, 1286-1306.
74. Lynch, M.J.; Baillie, G.S.; Mohamed, A.; Li, X.; Maisonneuve, C.; Klussmann, E.; Van, H.G.; Houslay, M.D. RNA silencing identifies PDE4D5 as the functionally relevant cAMP phosphodiesterase interacting with beta arrestin to control the protein kinase A/AKAP79- mediated switching of the beta2-adrenergic receptor to activation of ERK in HEK293B2 cells. J. Biol. Chem. 2005, 280, 33178-33189.
75. Lin, F.; Wang, H.; Malbon, C.C. Gravin-mediated formation of signaling complexes in beta2- adrenergic receptor desensitization and resensitization. J. Biol. Chem. 2000, 275, 19025-19034.
76. Anderson, G.P. Current issues with beta2-adrenoceptor agonists: pharmacology and molecular and cellular mechanisms. Clin. Rev. Allergy Immunol. 2006, 31, 119-130.
77. Cooper, D.M. Compartmentalization of adenylate cyclase and cAMP signalling. Biochem. Soc Trans. 2005, 33, 1319-1322.
78. Delint-Ramirez, I.; Willoughby, D.; Hammond, G.V.R.; Ayling, L.J.; Cooper, D.M.F. Palmitylation targets AKAP79 protein to lipid rafts and promotes its regulation of calcium- sensitive adenylyl cyclase type 8. J. Biol. Chem. 2011, 286, 32962-32975.
79. Dodge-Kafka, K.L.; Soughayer, J.; Pare, G.C.; Carlisle Michel, J.J.; Langeberg, L.K.; Kapiloff, M.S.; Scott, J.D. The protein kinase A anchoring protein mAKAP coordinates two integrated cAMP effector pathways. Nature 2005, 437, 574-578.
80. Nijholt, I.M.; Dolga, A.M.; Ostroveanu, A.; Luiten, P.G.; Schmidt, M.; Eisel, U.L. Neuronal AKAP150 coordinates PKA and Epac-mediated PKB/Akt phosphorylation. Cell Signal. 2008, 20, 1715-1724.
81. Cohen, P. Protein kinases--the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 2002, 1, 309-315.
82. Tasken, K.; Aandahl, E.M. Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol Rev. 2004, 84, 137-167.
83. Zambon, A.C.; Zhang, L.; Minovitsky, S.; Kanter, J.R.; Prabhakar, S.; Salomonis, N.; Vranizan, K.; Dubchak, I.; Conklin, B.R.; Insel, P.A. Gene expression patterns define key transcriptional events in cell-cycle regulation by cAMP and protein kinase A. Proc. Natl. Acad. Sci. USA 2005, 102, 8561-8566.
84. de Rooij, J.; Zwartkruis, F.J.; Verheijen, M.H.; Cool, R.H.; Nijman, S.M.; Wittinghofer, A.; Bos, J.L. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 1998, 396, 474-477.
85. Kawasaki, H.; Springett, G.M.; Mochizuki, N.; Toki, S.; Nakaya, M.; Matsuda, M.; Housman, D.E.; Graybiel, A.M. A family of cAMP-binding proteins that directly activate Rap1. Science 1998, 282, 2275-2279.
86. Krugmann, S.; Williams, R.; Stephens, L.; Hawkins, P.T. ARAP3 is a PI3K- and RAP-regulated GAP for RhoA. Curr. Biol. 2004, 14, 1380-1384.
87. Roscioni, S.S.; Maarsingh, H.; Elzinga, C.R.; Schuur, J.; Menzen, M.; Halayko, A.J.; Meurs, H.; Schmidt, M. Epac as a novel effector of airway smooth muscle relaxation. J. Cell Mol. Med. 2011, 15, 1551-1562.
88. Zieba, B.J.; Artamonov, M.V.; Jin, L.; Momotani, K.; Ho, R.; Franke, A.S.; Neppl, R.L.; Stevenson, A.S.; Khromov, A.S.; Chrzanowska-Wodnicka, M.; Somlyo, A.V. The cAMP- responsive Rap1 guanine nucleotide exchange factor, Epac, induces smooth muscle relaxation by down-regulation of RhoA activity. J. Biol. Chem. 2011, 286, 16681-16692.
89. Li, Y.; Asuri, S.; Rebhun, J.F.; Castro, A.F.; Paranavitana, N.C.; Quilliam, L.A. The RAP1 guanine nucleotide exchange factor Epac2 couples cyclic AMP and Ras signals at the plasma membrane. J. Biol. Chem. 2006, 281, 2506-2514.
90. Lopez De Jesus, M.; Stope, M.B.; Oude Weernink, P.A.; Mahlke, Y.; Borgermann, C.; Ananaba, V.N.; Rimmbach, C.; Rosskopf, D.; Michel, M.C.; Jakobs, K.H.; Schmidt, M. Cyclic AMP- dependent and Epac-mediated activation of R-Ras by G protein-coupled receptors leads to phospholipase D stimulation. J. Biol. Chem. 2006, 281, 21837-21847.
91. Oestreich, E.A.; Wang, H.; Malik, S.; Kaproth-Joslin, K.A.; Blaxall, B.C.; Kelley, G.G.; Dirksen, R.T.; Smrcka, A.V. Epac-mediated activation of phospholipase C(epsilon) plays a critical role in beta-adrenergic receptor-dependent enhancement of Ca2+ mobilization in cardiac myocytes. J. Biol. Chem. 2007, 282, 5488-5495.
92. Schmidt, M.; Evellin, S.; Weernink, P.A.; von, D.F.; Rehmann, H.; Lomasney, J.W.; Jakobs, K.H. A new phospholipase-C-calcium signalling pathway mediated by cyclic AMP and a Rap GTPase. Nat. Cell Biol. 2001, 3, 1020-1024.
93. Han, L.; Stope, M.B.; de Jesus, M.L.; Oude Weernink, P.A.; Urban, M.; Wieland, T.; Rosskopf, D.; Mizuno, K.; Jakobs, K.H.; Schmidt, M. Direct stimulation of receptor-controlled phospholipase D1 by phospho-cofilin. EMBO J. 2007, 26, 4189-4202.
94. Wang, C.; Gu, Y.; Li, G.W.; Huang, L.Y. A critical role of the cAMP sensor Epac in switching protein kinase signalling in prostaglandin E2-induced potentiation of P2X3 receptor currents in inflamed rats. J. Physiol. 2007, 584, 191-203.
95. Roscioni, S.S.; Kistemaker, L.E.; Menzen, M.H.; Elzinga, C.R.; Gosens, R.; Halayko, A.J.; Meurs, H.; Schmidt, M. PKA and Epac cooperate to augment bradykinin-induced interleukin-8 release from human airway smooth muscle cells. Respir. Res. 2009, 10, 88.
96. Roscioni, S.S.; Dekkers, B.G.; Prins, A.G.; Menzen, M.H.; Meurs, H.; Schmidt, M.; Maarsingh, H. cAMP inhibits modulation of airway smooth muscle phenotype via the exchange protein activated by cAMP (Epac) and protein kinase A. Br. J. Pharmacol. 2011, 162, 193-209.
97. Keiper, M.; Stope, M.B.; Szatkowski, D.; Bohm, A.; Tysack, K.; Vom, D.F.; Saur, O.; Oude Weernink, P.A.; Evellin, S.; Jakobs, K.H.; Schmidt, M. Epac- and Ca2+ -controlled activation of Ras and extracellular signal-regulated kinases by Gs-coupled receptors. J. Biol. Chem. 2004, 279, 46497-46508.
98. Kiermayer, S.; Biondi, R.M.; Imig, J.; Plotz, G.; Haupenthal, J.; Zeuzem, S.; Piiper, A. Epac activation converts cAMP from a proliferative into a differentiation signal in PC12 cells. Mol. Biol. Cell 2005, 16, 5639-5648.
99. Grandoch, M.; López de Jesús, M.; Oude Weernink, P.A.; Weber, A.-A.; Jakobs, K.H.; Schmidt, M. B cell receptor-induced growth arrest and apoptosis in WEHI-231 immature B lymphoma cells involve cyclic AMP and Epac proteins. Cell Signal. 2009, 4, 609-621.
100. Kwak, H.J.; Park, K.M.; Choi, H.E.; Chung, K.S.; Lim, H.J.; Park, H.Y. PDE4 inhibitor, roflumilast protects cardiomyocytes against NO-induced apoptosis via activation of PKA and Epac dual pathways. Cell Signal. 2008, 20, 803-814.
101. Mei, F.C.; Qiao, J.; Tsygankova, O.M.; Meinkoth, J.L.; Quilliam, L.A.; Cheng, X. Differential signaling of cyclic AMP: opposing effects of exchange protein directly activated by cyclic AMP and cAMP-dependent protein kinase on protein kinase B activation. J. Biol. Chem. 2002, 277, 11497-11504.
102. Misra, U.K.; Pizzo, S.V. Coordinate regulation of forskolin-induced cellular proliferation in macrophages by protein kinase A/cAMP-response element-binding protein (CREB) and Epac1- Rap1 signaling: effects of silencing CREB gene expression on Akt activation. J. Biol. Chem. 2005, 280, 38276-38289.
103. Misra, U.K.; Kaczowka, S.; Pizzo, S.V. The cAMP-activated GTP exchange factor, Epac1 upregulates plasma membrane and nuclear Akt kinase activities in 8-CPT-2-O-Me-cAMP- stimulated macrophages: Gene silencing of the cAMP-activated GTP exchange Epac1 prevents 8-CPT-2-O-Me-cAMP activation of Akt activity in macrophages. Cell Signal. 2008, 20, 1459-1470.
104. Hewer, R.C.; Sala-Newby, G.B.; Wu, Y.-J.; Newby, A.C.; Bond, M. PKA and Epac synergistically inhibit smooth muscle cell proliferation. J. Mol. Cell. Cardiol. 2011, 50, 87-98.
105. Fuld, S.; Borland, G.; Yarwood, S.J. Elevation of cyclic AMP in Jurkat T-cells provokes distinct transcriptional responses through the protein kinase A (PKA) and exchange protein activated by cyclic AMP (EPAC) pathways. Exp. Cell Res. 2005, 309, 161-173.
106. Scheibner, K.A.; Boodoo, S.; Collins, S.; Black, K.E.; Chan-Li, Y.; Zarek, P.; Powell, J.D.; Horton, M.R. The adenosine a2a receptor inhibits matrix-induced inflammation in a novel fashion. Am. J. Respir. Cell Mol. Biol. 2009, 40, 251-259.
107. Oldenburger, A.; Roscioni, S.S.; Jansen, E.; Menzen, M.H.; Halayko, A.J.; Timens, W.; Meurs, H.; Maarsingh, H.; Schmidt, M. Anti-inflammatory role of the cAMP effectors Epac and PKA: implications in chronic obstructive pulmonary disease. PLoS One 2012, e31574.
108. Borland, G.; Smith, B.O.; Yarwood, S.J. EPAC proteins transduce diverse cellular actions of cAMP. Br. J. Pharmacol. 2009, 158, 70-86.
109. Grandoch, M.; Roscioni, S.S.; Schmidt, M. The role of Epac proteins, novel cAMP mediators, in the regulation of immune, lung and neuronal functions. Br. J. Pharmacol. 2010, 159, 265-284.
110. Roscioni, S.S.; Elzinga, C.R.; Schmidt, M. Epac: effectors and biological functions. Naunyn Schmiedebergs Arch. Pharmacol. 2008, 377, 345-357.
111. Schmidt, M.; Sand, C.; Jakobs, K.H.; Michel, M.C.; Oude Weernink, P.A. Epac and the cardiovascular system. Curr. Opin. Pharmacol. 2007, 7, 193-200.
112. Lorenowicz, M.J.; Fernandez-Borja, M.; Hordijk, P.L. cAMP signaling in leukocyte transendothelial migration. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 1014-1022.
113. Billington, C.K.; Hall, I.P.; Mundell, S.J.; Parent, J.L.; Panettieri, R.A., Jr.; Benovic, J.L.; Penn, R.B. Inflammatory and contractile agents sensitize specific adenylyl cyclase isoforms in human airway smooth muscle. Am. J. Respir. Cell Mol. Biol. 1999, 21, 597-606.
114. Bogard, A.S.; Xu, C.; Ostrom, R.S. Human bronchial smooth muscle cells express adenylyl cyclase isoforms 2, 4, and 6 in distinct membrane microdomains. J. Pharmacol Exp. Ther. 2011, 337, 209-217.
115. Xu, D.; Isaacs, C.; Hall, I.P.; Emala, C.W. Human airway smooth muscle expresses 7 isoforms of adenylyl cyclase: a dominant role for isoform V. Am. J. Physiol Lung Cell Mol. Physiol 2001, 281, L832-L843.
116. Le Jeune, I.; Shepherd, M.; Van, H.G.; Houslay, M.D.; Hall, I.P. Cyclic AMP-dependent transcriptional up-regulation of phosphodiesterase 4D5 in human airway smooth muscle cells. Identification and characterization of a novel PDE4D5 promoter. J. Biol. Chem. 2002, 277, 35980-35989.
117. Horvat, S.J.; Deshpande, D.A.; Yan, H.; Panettieri, R.A.; Codina, J.; DuBose, T.D.; Xin, W.; Rich, T.C.; Penn, R.B. A-kinase anchoring proteins regulate compartmenalized cAMP signaling in airway smooth muscle. FASEB J. 2012, 9, 3670-3679
118. Liu, X.; Ostrom, R.S.; Insel, P.A. cAMP-elevating agents and adenylyl cyclase overexpression promote an antifibrotic phenotype in pulmonary fibroblasts. Am. J. Physiol Cell Physiol. 2004, 286, C1089-C1099.
119. Selige, J.; Hatzelmann, A.; Dunkern, T. The differential impact of PDE4 subtypes in human lung fibroblasts on cytokine-induced proliferation and myofibroblast conversion. J. Cell Physiol. 2011, 226, 1970-1980.
120. Selige, J.; Tenor, H.; Hatzelmann, A.; Dunkern, T. Cytokine-dependent balance of mitogenic effects in primary human lung fibroblasts related to cyclic AMP signaling and phosphodiesterase 4 inhibition. J. Cell Physiol. 2010, 223, 317-326.
121. Togo, S.; Liu, X.; Wang, X.; Sugiura, H.; Kamio, K.; Kawasaki, S.; Kobayashi, T.; Ertl, R.F.; Ahn, Y.; Holz, O.; Magnussen, H.; Fredriksson, K.; Skold, C.M.; Rennard, S.I. PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts. Am. J. Physiol. Lung Cell Mol. Physiol. 2009, 296, L959-L969.
122. Okunishi, K.; Sisson, T.H.; Huang, S.K.; Hogaboam, C.M.; Simon, R.H.; Peters-Golden, M. Plasmin overcomes resistance to prostaglandin E2 in fibrotic lung fibroblasts by reorganizing protein kinase A signaling. J. Biol. Chem. 2011, 286, 32231-32243.
123. Tasken, K.A.; Collas, P.; Kemmner, W.A.; Witczak, O.; Conti, M.; Tasken, K. Phosphodiesterase 4D and protein kinase a type II constitute a signaling unit in the centrosomal area. J. Biol. Chem. 2001, 276, 21999-22002.
124. Calverley, P.M.; Rabe, K.F.; Goehring, U.M.; Kristiansen, S.; Fabbri, L.M.; Martinez, F.J. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009, 374, 685-694.
125. Spina, D. PDE4 inhibitors: current status. Br. J. Pharmacol. 2008, 155, 308-315.
126. Michalski, J.M.; Golden, G.; Ikari, J.; Rennard, S.I. PDE4: A novel target in the treatment of chronic obstructive pulmonary disease. Clin. Pharmacol. Ther. 2011, doi: 10.1038/clpt.2011.266.
127. Li, Y.; Chen, L.; Kass, R.S.; Dessauer, C.W. The A-kinase anchoring protein Yotiao facilitates complex formation between adenylyl cyclase type 9 and the IKs potassium channel in heart. J Biol. Chem. 2012, 287, 29815-29824.
128. Qin, Y.; Stokman, G.; Yan, K.; Ramaiahgari, S.; Verbeek, F.; de Graauw, M.; van de Water, B.; Price, L.S. Cyclic AMP signalling protects proximal tubular epithelial cells from cisplatin- induced apoptosis via activation of Epac. Br. J. Pharmacol. 2011, DOI: 10.1111/j.1476-5381.2011.01594.x.
129. Roscioni, S.S. Epac as a novel regulator of airway smooth muscle phenotype and function. Potential implications in asthma and COPD. Ph.D. Degree, University of Groningen, The Netherland, 2010.
130. Oldenburger, A.; Rijks, W.; Poppinga, W.; Roscioni, S.S.; Heijink, I.H.; Maarsingh, H.; Schmidt, M. Interaction between cigarette smoke and cyclic AMP signaling in human bronchial epithelial function. FASEB J. 2011, 25, 659.13.
131. Dent, G.; White, S.R.; Tenor, H.; Bodtke, K.; Schudt, C.; Leff, A.R.; Magnussen, H.; Rabe, K.F. Cyclic nucleotide phosphodiesterase in human bronchial epithelial cells: characterization of isoenyzmes and functional effects of PDE inhibitors. Pulm. Pharmacol. Ther. 1998, 11, 47-56.
132. Mata, M.; Sarria, B.; Buenestado, A.; Cortijo, J.; Cerda, M.; Morcillo, E.J. Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells. Thorax 2005, 60, 144-152.
133. Barnes, A.P.; Livera, G.; Huang, P.; Sun, C.; O'Neal, W.K.; Conti, M.; Stutts, M.J.; Milgram, S.L. Phosphodiesterase 4D forms a cAMP diffusion barrier at the apical membrane of the airway epithelium. J. Biol. Chem. 2005, 280, 7997-8003.
134. Penmatsa, H.; Zhang, W.; Yarlagadda, S.; Li, C.; Conoley, V.G.; Yue, J.; Bahouth, S.W.; Buddington, R.K.; Zhang, G.; Nelson, D.J.; Sonecha, M.D.; Manganiello, V.; Wine, J.J.; Naren, A.P. Compartmentalized cyclic adenosine 3', 5'-monophosphate at the plasma membrane clusters PDE3A and cystic fibrosis transmembrane conductance regulator into microdomains. Mol. Biol Cell 2010, 21, 1097-1110.
135. Halpin, D.M. ABCD of the phosphodiesterase family: interaction and differential activity in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2008, 3, 543-561.
136. Small, K.M.; Brown, K.M.; Theiss, C.T.; Seman, C.A.; Weiss, S.T.; Liggett, S.B. An Ile to Met polmorphism in the catalytic domain of adenylyl cycalse type 9 confers reduced beta2-adrenergic receptor stimulation. Pharmacogenetics 2003, 13, 535-541.
137. Tantisira, K.G.; Small, K.M.; Litonjua, A.A.; Weiss, S.T.; Liggett, S.B. Molecular properties and pharmacogenetics of a polymorphism of adenylyl cyclase type 9 in asthma: interaction between b-agonist and corticosteroid pathways. Hum. Mol. Genet. 2005, 14, 1671-1677.
138. Jourdan, K.B.; Mason, N.A.; Long, L.; Philips, P.G.; Wilkins, M.R.; Morrell, N.W. Characterization of adenylyl cyclase isoforms in rat peripheral pulmonary arteries. Am. J. Physiol Lung Cell Mol. Physiol. 2001, 280, L1359-L1369.
139. Wang, Y.; Lam, C.S.; Wu, F.; Wang, W.; Duan, Y.; Huang, P. Regulation of CFTR channels by HCO(3)--sensitive soluble adenylyl cyclase in human airway epithelial cells. Am. J. Physiol. Cell. Physiol. 2005, 289, C1145-C1151.
140. Blazac, F.; Avolio, M.; Degani, S.; Kaverina, I.; Torti, M.; Silengo, L.; Small, J.V.; Retta, S.F. E- cadherin endocytosis regulates the activity of Rap1: a traffic light GTPase at the croosraods between cadherin and integrin function. J. Cell Sci. 2005, 118, 4765-4783.
141. Hage, B.; Meinel, K.; Baum, I.; Giehl, K.; Menke, A. Rac1 activation inhibits E-cadherin- mediated adherens junctions via binding to IQGAP1 in pancreatic carcinoma cells. Cell Commun. Signal. 2009, 7, 23.
142. Smutny, M.; Cox, L.H.; Leerberg, J.M.; Kovacs, E.M.; Conti, M.A.; Ferguson, C.; Hamilton, N.A.; Parton, R.G.; Adelstein, R.S.; Yap, A.S. Myosin II isoforms identify distinct functional modules that support integrity of the epithelial zonula adherens. Nat. Cell Biol. 2010, 12, 696-702.
143. Jeong, H.-W.; Li, Z.; Brown, M.D.; Sacks, D.B. IQGAP1 binds Rap1 and modulates its activity. J. Biol. Chem. 2007, 282, 20752-20762.
144. Kuroda, S.; Fukata, M.; Nakagawa, M.; Fuji, K.; Nakmura, T.; Ookubo, T.; Izawa, I.; Nagase, T.; Nomura, N.; Tani, H.; Shoji, I.; Matsuura, Y.; Ynoehara, S.; Kaibuchi, K. Role of IQGAP1, a target of the small GTPases Cdc42 and Rac1, in regulation of E-cadherin mediated cell-cell adhesion. Science 1998, 281, 832-835.
145. Noritake, J.; Watanbe, T.; Sato, K.; Wang, S.; Kaibuchi, K. IQGAP1: a key regulator of adhesion and migration. J. Cell Sci. 2005, 118, 2085-2092.
146. Birukova, A.A.; Burdette, D.; Moldobaeva, N.; Xing, J.; Fu, P.; Birukov, K.G. Rac GTPase is a hub for protein kinase A and epac signaling in endothelial barrier protection by cAMP. Microvascul. Res. 2010, 79, 128-138.
147. Rampersad, S.N.; Ovens, J.D.; Huston, E.; Umana, M.B.; Wilson, L.S.; Netherton, S.J.; Lynch, M.J.; Baillie, G.S.; Houslay, M.D.; Maurice, D.H. Cyclic AMP phosphodieseterase 4D (PDE4D) tethers EPAC1 in a vascular endothelial cadherin (VE-Cad)-based signaling complex and controls cAMP-mediated vascular permeabilbity. J. Biol. Chem. 2010, 285, 33614-33622.
148. Sehrawat, S.; Cullere, X.; Patel, S.; Italiano, J.; Mayadas, T.N. Role of Epac1, an exchange factor for rap GTPases, in endothelial microtubule dynamics and barrier function. Mol. Biol. Cell 2008, 19, 1261-1270.
149. Sehrawat, S.; Ernandez, T.; Cullere, X.; Takahashi, M.; Ono, Y.; Komarova, Y.; Mayadas, T.N. AKAP9 regulation of microtubule dynamics promotes Epac1-induced endothelial barrier properties. Blood 2011, 117, 708-718.
150. Diviani, D.; Soderling, J.; Scott, J.D. AKAP-Lbc anchors protein kinase A and nucleates Galpha 12-selective Rho-mediated stress fiber formation. J. Biol. Chem. 2001, 276, 44247-44257.
151. Suh, H.N.; Han, H.J. Laminin regulates mouse embryonic stem cell migration: involvement of Epac1/Rap1 and Ra1/cdc42. Am. J. Physiol. Cell Physiol. 2010, 298, C1159-C1169.
152. Netherton, S.J.; Sutton, J.A.; Wilson, L.S.; Carter, R.L.; Maurice, D.H. Both protein kinase A and exchange protein directly activated by cAMP coordinate adhesion of human vascular endothelial cells. Circ. Res. 2007, 101, 768-776.
153. Baumer, Y.; Spindler, V.; Werthmann, R.C.; Bünnemann, M.; Waschke, J. Role of Rac1 and cAMP in endothelial barrier stabilization and thrombin-induced barrier breakdown. J. Cell. Physiol. 2008, 220, 716-726.
154. Pullar, C.E.; Grahn, J.C.; Liu, W.; Isseroff, R.R. b2-Adrenergic receptor activation delays wound healing. FASEB J. 2004, 20, 76-86.
155. Raymond, D.R.; Wilson, L.S.; Carter, R.L.; Maurice, D.H. Numerous distinct PKA-, or Epac- based, signalling complexes allow selective phosphodiesterase 3 and phosphodiesterase 4 coordination of cell adhesion. Cell Signal. 2007, 19, 2507-2512.
156. Spindler, V.; Waschke, J. Beta-adrenergic stimulation contributes to maintenance of endothelial barrier functions under baseline conditions. Microcirculation 2011, 18, 118-127.
157. Spindler, V.; Peter, D.; Harms, G.S.; Asan, E.; Waschke, J. Ultrastructural analysis reveals cAMP-dependent enhancement of microvascular endothelial barrier functions via Rac1-mediated reorganization of intercellular junctions. Am. J. Pathol. 2011, 178, 2424-2436.
158. Schlegel, N.; Waschke, J. VASP is involved in cAMP-mediated rac 1 activation in microvascular endothelial cells. Am. J. Cell Physiol. 2009, 296, C453-C462.
159. Cole, A.L.; Subbanagounder, G.; Mukhopadhyay, S.; Berliner, J.A.; Vora, D.K. Oxidized phospholipid-induced endothelial cell/monocyte interaction is mediated by a cAMP-dependent R-Ras/PI3-kinase pathway. Arterioscler. Thromb. Vasc. Biol. 2003, 23, 1384-1390.
160. Poppinga, W.J.; Holtzer, L.J.; Skroblin, P.; Klussmann, E.; Maarsingh, H.; Schmidt, M. A-kinase anchoring proteins (AKAPs) regulate airway smooth muscle sceretory and proliferative functions. Available oneline, http://www.pA2online.org/abstracts/Vol10Issue1abst004P.pdf, accessed on 28 November 2012.
161. Omori, K.; Kotera, J. Overview of PDEs and their regulation. Circ. Res. 2007, 100, 309-327.
162. Purves, G.I.; Kamishima, T.; Davies, L.M.; Quayle, J.M.; Dart, C. Exchange protein activated by cAMP (Epac) mediates cAMP-dependent but protein kinase A-insensitive modulation of vascular ATP-sensitive potassium channels. J. Physiol. 2009, 587, 3639-3650.
163. Streb, J.W.; Long, X.; Lee, T.H.; Sun, Q.; Kitchen, C.M.; Georger, M.A.; Slivano, O.J.; Blaner, W.S.; Carr, D.W.; Gelman, I.H.; Miano, J.M. Retinoid-induced expression and activity of an immediate early tumor suppressor gene in vascular smooth muscle cells. PLos One 2011, 6, e18538.
164. Murray, F.; Patel, H.H.; Suda, R.Y.; Zhang, S.; Thistlethwaite, P.A.; Yuan, J.X.; Insel, P.A. Expression and activity of cAMP phosphodiesterase isoforms in pulmonary artery smooth muscle cells from patients with pulmonary hypertension: role for PDE1. Am. J. Physiol. Lung Cell Mol. Physiol. 2007, 292, L294-L303.
165. El-Haroun, H.; Bradbury, D.; Clayton, A.; Knox, A.J. Interleukin-1beta, transforming growth factor-beta1, and bradykinin attenuate cyclic AMP production by human pulmonary artery smooth muscle cells in response to prostacyclin analogues and prostaglandin E2 by cyclooxygenase-2 induction and downregulation of adenylyl cyclase isoforms 1, 2, and 4. Circ. Res. 2004, 94, 353-361.
166. Yokoyama, U.; Minamisawa, S.; Quan, H.; Akaike, T.; Jin, M.; Otsu, K.; Ulucan, C.; Wang, X.; Baljinnyam, E.; Takaoka, M.; Sata, M.; Ishikawa, Y. Epac1 is upregulated during neointima formation and promotes vascular smooth muscle cell migration. Am. J. Physiol. Heart. Circ. Physiol. 2008, 295, H1547-H1555.
167. Diebold, I.; Petry, A.; Djordjevic, T.; Belaiba, R.S.; Fineman, J.; Black, S.; Schreiber, C.; Fratz, S.; Hess, J.; Kietzmann, T.; Gorlach, A. Reciprocal regulation of Rac1 and PAK-1 by HIF-1alpha: a positive-feedback loop promoting pulmonary vascular remodeling. Antioxid. Redox. Signal. 2010, 13, 399-412.
168. Bailly, K.; Ridley, A.J.; Hall, S.M.; Haworth, S.G. RhoA activation by hypoxia in pulmonary arterial smooth muscle cells is age and site specific. Circ. Res. 2004, 94, 1383-1391.
169. Guilluy, C.; Eddahibi, S.; Agard, C.; Guignabert, C.; Izikki, M.; Tu, L.; Savale, L.; Humbert, M.; Fadel, E.; Adnot, S.; Loirand, G.; Pacaud, P. RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling. Am. J. Respir. Crit. Care. Med. 2009, 179, 1151-1158.
170. Haag, S.; Warnken, M.; Juergens, U.R.; Racke, K. Role of Epac1 in mediating anti-proliferative effects of prostanoid EP(2) receptors and cAMP in human lung fibroblasts. Naunyn Schmiedebergs Arch. Pharmacol. 2008, 378, 617-630.
171. Kohyama, T.; Liu, X.; Wen, F.Q.; Zhu, Y.K.; Wang, H.; Kim, H.J.; Takizawa, H.; Cieslinski, L.B.; Barnette, M.S.; Rennard, S.I. PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels. Am. J. Respir. Cell Mol. Biol. 2002, 26, 694-701.
172. Tufvesson, E.; Westergren-Thorsson, G. Biglycan and decorin induce morphological and cytoskeletal changes involving signalling by the small GTPases RhoA and Rac1 resulting in lung fibroblast migration. J. Cell Sci. 2003, 116, 4857-4864.
173. Huang, S.K.; Wettlaufer, S.H.; Chung, J.; Peters-Golden, M. Prostaglandin E2 inhibits specific lung fibroblast functions via selective actions of PKA and Epac-1. Am. J. Respir. Cell Mol. Biol. 2008, 39, 482-489.
174. Brudvik, K.W.; Tasken, K. Modulation of T cell immune functions by the prostaglandin E(2) - cAMP pathway in chronic inflammatory states. Br. J. Pharmacol. 2012, 166, 411-419
175. El Din El Homasany B.S.; Volkov, Y.; Takahashi, M.; Ono, Y.; Keryer, G.; Delouvee, A.; Looby, E.; Long, A.; Kelleher, D. The scaffolding protein CG-NAP/AKAP450 is a critical integrating component of the LFA-1-induced signaling complex in migratory T cells. J. Immunol. 2005, 175, 7811-7818.
176. Wang, P.; Wu, P.; Ohleth, K.M.; Egan, R.W.; Billah, M.M. Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. Mol. Pharmacol. 1999, 56, 170-174.
177. Smith, S.J.; Brookes-Fazakerley, S.; Donnelly, L.E.; Barnes, P.J.; Barnette, M.S.; Giembycz, M.A. Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells. Am J Physiol Lung Cell Mol. Physiol. 2003, 284, L279-L289.
178. Mosenden, R.; Tasken, K. Cyclic AMP-mediated immune regulation--overview of mechanisms of action in T cells. Cell Signal. 2011, 23, 1009-1016.
179. Chang, L.C.; Wang, C.J.; Lin, Y.L.; Wang, J.P. Expression of adenylyl cyclase isoforms in neutrophils. Biochim. Biophys. Acta 2003, 1640, 53-60.
180. Risoe, P.K.; Wang, Y.; Stuestol, J.F.; Aasen, A.O.; Wang, J.E.; Dahle, M.K. Lipopolysaccharide attenuates mRNA levels of several adenylyl cyclase isoforms in vivo. Biochim. Biophys. Acta 2007, 1772, 32-39.
181. Han, H.; Stessin, A.; Roberts, J.; Hess, K.; Gautam, N.; Kamenetsky, M.; Lou, O.; Hyde, E.; Nathan, N.; Muller, W.A.; Buck, J.; Levin, L.R.; Nathan, C. Calcium-sensing soluble adenylyl cyclase mediates TNF signal transduction in human neutrophils. J. Exp. Med. 2005, 202, 353-361.
182. Reedquist, K.A.; Tak, P.P. Signal transduction pathways in chronic inflammatory autoimmune disease: small GTPases. Open. Rheumatol. J. 2012, 6, 259-272.
183. Zhang, J.; Zhu, J.; Bu, X.; Cushion, M.; Kinane, T.B.; Avraham, H.; Koziel, H. Cdc42 and RhoB activation are required for mannose receptor-mediated phagocytosis by human alveolar macrophages. Mol. Biol. Cell 2005, 16, 824-834.
184. Pierre, S.; Eschenhagen, T.; Geisslinger, G.; Scholich, K. Capturing adenylyl cyclases as potential drug targets. Nat Rev. Drug Discov. 2009, 8, 321-335.
185. Defer, N.; Best-Belpomme, M.; Hanoune, J. Tissue specificity and physiological relevance of various isoforms of adenylyl cyclase. Am. J. Renal Physiol. 2000, 279, F400-F416.
186. Schmid, A.; Sutto, Z.; Nlend, M.-C.; Horvath, G.; Schmid, N.; Buck, J.; Levin, L.R.; Conner, G.E.; Fregien, N.; Salathe, M. Soluble adenylyl cyclase is localized to cilia and contributes to ciliary beat frequency regulation via production of cAMP. J. Gen. Physiol. 2007, 130, 99-109.
187. Lopez, E.; Jarreau, P.-H.; Zana, E.; Franco-Montoya, M.-L.; Schmitz, T.; Evain-Brion, D.; Bourbon, J.; Delacourt, C.; Mehats, C. Differential expression of cyclic nucleotide phosphodiesterases 4 in developing rat lung. Develop. Dynam. 2010, 239, 2470-2478.
188. Hoque, K.M.; Woodward, O.M.; van Rossum, D.B.; Zachos, N.C.; Chen, L.; Leung, G.P.; Guggino, W.B.; Guggino, S.E.; Tse, C.M. Epac1 mediates protein kinase A-independent mechanism of forskolin-activated intestinal chloride secretion. J. Gen. Physiol. 2010, 135, 43-58.
189. Monterisi, S.; Favia, M.G.L.; Cardone, R.A.; Marzulli, D.; Reshkin, S.J.; Casavola, V.; Zaccolo, M. CFTR regulation in human airway epithelial cells requires integrity of the actin cytoskeleton and compartmentalized cAMP and PKA activity. J. Cell Sci. 2012, 125, 1106-1117.
190. Li, C.; Krishnamurthy, P.C.; Penmatsa, H.; Marrs, K.L.; Wang, X.Q.; Zaccolo, M.; Jalink, K.; Li, M.; Nelson, D.J.; Schuetz, J.D.; Naren, A.P. Spatiotemporal coupling of cAMP transporter to CFTR chloride channel function in the gut epithelia. Cell 2007, 131, 940-951.
191. Schmidt, M.; Oldenburger, A.; Poppinga, W.; Roscioni, S.S.; Heijink, I.H.; Timens, W.; Skroblin, P.; Klussmann, E.; Maarsingh, H. Cigarette smoke and A-kinase anchoring proteins (AKAPs) in human airway smooth muscle function. FASEB J. 2011, 25, 864.6.
192. Patel, H.H.; Hamuro, L.L.; Chun, B.J.; Kawaraguchi, Y.; Quick, A.; Olson, G.; Insel, P.A.; Giles, W.R.; Taylor, S.S.; Roth, D.M. Disruption of protein kinase A localization using a trans-activator of transcription (TAT)-conjugated A-kinase-anchoring peptide reduces cardiac function. J. Biol. Chem. 2010, 285, 27632-27640.
193. Christian, F.; Sazaszák, M.; Friedl, S.; Drewianka, S.; Lorenz, D.; Goncalves, A.; Furkert, J.; Vargas, C.; Schmieder, P.; Götz, F.; Zühlke, K.; Moutty, M.; Göttert, H.; Gáspàr, R.; Noack, C.; Bergmann, M.; Kass, R.; Hampel, K.; Kashin, D.; Genieser, H.-G.; Herberg, F.W.; Willoughby, D.; Cooper, D.M.F.; Baillie, G.S.; Houslay, M.D.; von Kries, J.P.; Zimmermann, B.; Rosenthal, W.; Klussmann, E. Small molecule AKAP-protein kinase A (PKA) interaction disruptors that activate PKA interfere with compartmentalized cAMP signaling in cardiac myocytes. J. Biol. Chem. 2011, 286, 9079-9096.
194. Christensen, A.E.; Selheim, F.; de, R.J.; Dremier, S.; Schwede, F.; Dao, K.K.; Martinez, A.; Maenhaut, C.; Bos, J.L.; Genieser, H.G.; Doskeland, S.O. cAMP analog mapping of Epac1 and cAMP kinase. Discriminating analogs demonstrate that Epac and cAMP kinase act synergistically to promote PC-12 cell neurite extension. J. Biol. Chem. 2003, 278, 35394-35402.
195. Poppe, H.; Rybalkin, S.D.; Rehmann, H.; Hinds, T.R.; Tang, X.B.; Christensen, A.E.; Schwede, F.; Genieser, H.G.; Bos, J.L.; Doskeland, S.O.; Beavo, J.A.; Butt, E. Cyclic nucleotide analogs as probes of signaling pathways. Nat. Methods 2008, 5, 277-278.
196. Botelho, L.H.; Rothermel, J.D.; Coombs, R.V.; Jastorff, B. cAMP analog antagonists of cAMP action. Methods Enzymol. 1988, 159, 159-172.
197. Gjertsen, B.T.; Mellgren, G.; Otten, A.; Maronde, E.; Genieser, H.G.; Jastorff, B.; Vintermyr, O.K.; McKnight, G.S.; Doskeland, S.O. Novel (Rp)-cAMPS analogs as tools for inhibition of cAMP-kinase in cell culture. Basal cAMP-kinase activity modulates interleukin-1 beta action. J. Biol. Chem. 1995, 270, 20599-20607.
198. Holz, G.G.; Chepurny, O.G.; Schwede, F. Epac-selective cAMP analogs: new tools with which to evaluate the signal transduction properties of cAMP-regulated guanine nucleotide exchange factors. Cell Signal. 2008, 20, 10-20.
199. Rehmann, H.; Schwede, F.; Doskeland, S.O.; Wittinghofer, A.; Bos, J.L. Ligand-mediated activation of the cAMP-responsive guanine nucleotide exchange factor Epac. J. Biol. Chem. 2003, 278, 38548-38556.
200. Laxman, S.; Riechers, A.; Sadilek, M.; Schwede, F.; Beavo, J.A. Hydrolysis products of cAMP analogs cause transformation of Trypanosoma brucei from slender to stumpy-like forms. Proc. Natl. Acad. Sci. USA 2006, 103, 19194-19199.
201. Shibasaki, T.; Takahashi, H.; Miki, T.; Sunaga, Y.; Matsumura, K.; Yamanaka, M.; Zhang, C.; Tamamoto, A.; Satoh, T.; Miyazaki, J.; Seino, S. Essential role of Epac2/Rap1 signaling in regulation of insulin granule dynamics by cAMP. Proc. Natl. Acad. Sci. USA 2007, 104, 19333-19338.
202. Suzuki, S.; Yokoyama, U.; Abe, T.; Kiyonari, H.; Yamashita, N.; Kato, Y.; Kurotani, R.; Sato, M.; Okumura, S.; Ishikawa, Y. Differential roles of Epac in regulating cell death in neuronal and myocardial cells. J. Biol. Chem. 2010, 285, 24248-24259.
203. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Diagnosis, Management, and Prevention of COPD, 2010, Available online: http://www.goldcopd.org/, accessed on 28 November 2013.
204. Postma, D.S.; Timens, W. Remodeling in asthma and chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2006, 3, 434-439.
205. Briggs, M.W.; Sacks, D.B. IQGAPs proteins are integral components of cytoskeletal regulation. EMBO Reports 2003, 4, 571-574.
206. Doherty, D.E. The pathophysiology of airway dysfunction. Am. J. Med. 2004, 117 Suppl 12A, 11S-23S.
207. Rabe, K.F.; Hurd, S.S.; Anzueto, A.; Barnes, P.J.; Buist, S.A.; Calverley, P.; Fukuchi, Y.; Jenkins, C.; Rodriguez-Roisin, R.; van Weel, C.; Zielinski, J. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit Care Med. 2007, 176, 532-555.
208. Barnes, P.J.; Shapiro, S.D.; Pauwels, R.A. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur. Respir J. 2003, 22, 672-688.
209. Mannino, D.M. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest 2002, 121, 121S-126S.
210. Shin, H.J.; Sohn, H.O.; Han, J.H.; Park, C.H.; Lee, H.S.; Hwang, K.J.; Hyun, H.C. Effect of cigarette filters on the chemical composition and in vitro biological activity of cigarette mainstream smoke. Food Chem. Toxicol. 2009, 47, 192-197.
211. Domagala-Kulawik, J. Effects of cigarette smoke on the lung and systemic immunity. J. Physiol. Pharmacol. 2008, 59 Suppl 6, 19-34.
212. Thorley, A.J.; Tetley, T.D. Pulmonary epithelium, cigarette smoke, and chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 2007, 2, 409-428.
213. Crosby, L.M.; Waters, C.M. Epithelial repair mechanisms in the lung. Am. J. Physiol Lung Cell Mol. Physiol. 2010, 298, L715-L731.
214. Kode, A.; Yang, S.R.; Rahman, I. Differential effects of cigarette smoke on oxidative stress and proinflammatory cytokine release in primary human airway epithelial cells and in a variety of transformed alveolar epithelial cells. Respir. Res. 2006, 7, 132.
215. Oenema, T.A.; Kolahian, S.; Nanninga, J.E.; Rieks, D.; Hiemstra, P.S.; Zuyderduyn, S.; Halayko, A.J.; Meurs, H.; Gosens, R. Pro-inflammatory mechanisms of muscarinic receptor stimulation in airway smooth muscle. Respir. Res. 2010, 11, 130.
216. Pease, J.E.; Sabroe, I. The role of interleukin-8 and its receptors in inflammatory lung disease: Implications for therapy. Am. J. Respir. Med. 2002, 1, 19-25.
217. Taylor, J.D. COPD and the response of the lung to tobacco smoke exposure. Pulm. Pharmacol. Ther. 2010, 23, 376-383.
218. Cornwell, W.D.; Kim, V.; Song, C.; Rogers, T.J. Pathogenesis of inflammation and repair in advanced COPD. Semin. Respir. Crit. Care Med 2010, 31, 257-266.
219. Postma, D.S.; Kerstjens, H.A. Characteristics of airway hyperresponsiveness in asthma and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998, 158, S187-S192.
220. Tashkin, D.P.; Altose, M.D.; Connett, J.E.; Kanner, R.E.; Lee, W.W.; Wise, R.A. Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group. Am. J. Respir. Crit. Care Med. 1996, 153, 1802-1811.
221. Tashkin, D.P.; Altose, M.D.; Bleecker, E.R.; Connett, J.E.; Kanner, R.E.; Lee, W.W.; Wise, R. The lung health study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. The Lung Health Study Research Group. Am. Rev. Respir. Dis. 1992, 145, 301-310.
222. Saetta, M.; Di, S.A.; Turato, G.; Facchini, F.M.; Corbino, L.; Mapp, C.E.; Maestrelli, P.; Ciaccia, A.; Fabbri, L.M. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am. J. Respir. Crit Care Med. 1998, 157, 822-826.
223. Bosken, C.H.; Wiggs, B.R.; Pare, P.D.; Hogg, J.C. Small airway dimensions in smokers with obstruction to airflow. Am. Rev. Respir. Dis. 1990, 142, 563-570.
224. Cosio, M.G.; Hale, K.A.; Niewoehner, D.E. Morphologic and morphometric effects of prolonged cigarette smoking on the small airways. Am. Rev. Respir. Dis. 1980, 122, 266-271.
225. Saetta, M.; Turato, G.; Baraldo, S.; Zanin, A.; Braccioni, F.; Mapp, C.E.; Maestrelli, P.; Cavallesco, G.; Papi, A.; Fabbri, L.M. Goblet cell hyperplasia and epithelial inflammation in peripheral airways of smokers with both symptoms of chronic bronchitis and chronic airflow limitation. Am. J. Respir. Crit. Care Med. 2000, 161, 1016-1021.
226. Lambert, R.K.; Wiggs, B.R.; Kuwano, K.; Hogg, J.C.; Pare, P.D. Functional significance of increased airway smooth muscle in asthma and COPD. J. Appl. Physiol. 1993, 74, 2771-2781.
227. Jeffery, P.K. Remodeling in asthma and chronic obstructive lung disease. Am. J. Respir. Crit Care Med. 2001, 164, S28-S38.
228. Jeffery, P.K. Comparison of the structural and inflammatory features of COPD and asthma. Giles F. Filley Lecture. Chest 2000, 117, 251S-260S.
229. Barbera, J.A.; Blanco, I. Pulmonary hypertension in patients with chronic obstructive pulmonary disease: advances in pathophysiology and management. Drugs 2009, 69, 1153-1171.
230. Barnes, P.J. Mechanisms in COPD: differences from asthma. Chest 2000, 117, 10S-14S.
231. Finlay, G.A.; Russell, K.J.; McMahon, K.J.; D'arcy, E.M.; Masterson, J.B.; FitzGerald, M.X.; O'Connor, C.M. Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients. Thorax 1997, 52, 502-506.
232. Ohnishi, K.; Takagi, M.; Kurokawa, Y.; Satomi, S.; Konttinen, Y.T. Matrix metalloproteinase- mediated extracellular matrix protein degradation in human pulmonary emphysema. Lab. Invest. 1998, 78, 1077-1087.
233. Matsuba, K.; Thurlbeck, W.M. The number and dimensions of small airways in emphysematous lungs. Am. J. Pathol. 1972, 67, 265-275.
234. Wynn, T.A. Integrating mechanisms of pulmonary fibrosis. J. Exp. Med. 2011, 208, 1339-1350.
235. Salazar, L.M.; Herrera, A.M. Fibrotic response of tissue remodeling in COPD. Lung 2011, 189, 101-109.
236. Coraux, C.; Roux, J.; Jolly, T.; Birembaut, P. Epithelial cell-extracellular matrix interactions and stem cells in airway epithelial regeneration. Proc. Am. Thorac. Soc. 2008, 5, 689-694.
237. Fernandes, D.J.; Bonacci, J.V.; Stewart, A.G. Extracellular matrix, integrins, and mesenchymal cell function in the airways. Curr. Drug Targets 2006, 7, 567-577.
238. Jeffery, P.K. Remodeling and inflammation of bronchi in asthma and chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2004, 1, 176-183.
239. Mauad, T.; Dolhnikoff, M. Pathologic similarities and differences between asthma and chronic obstructive pulmonary disease. Curr. Opin. Pulm. Med. 2008, 14, 31-38.
240. Knight, D.A.; Holgate, S.T. The airway epithelium: Structural and functional properties in health and disease. Respirology 2003, 8, 432-446.
241. Petecchia, L.; Sabatini, F.; Varesio, L.; Camoirano, A.; Usai, C.; Pezzolo, A.; Rossi, G.A. Bronchial airway epithelial cell damage following exposure to cigarette smoke includes disassembly of tight junction components mediated by the extracellular signal-regulated kinase 1/2 pathway. Chest 2009, 135, 1502-1512.
242. Giembycz, M.A.; Kaur, M.; Leigh, R.; Newton, R. A Holy Grail of asthma management: toward understanding how long-acting beta(2)-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids. Br. J. Pharmacol. 2008, 153, 1090-1104.
243. Barnes, P.J. New therapies for chronic obstructive pulmonary disease. Med. Princ. Pract. 2010, 19, 330-338.
244. Pauwels, R.A.; Buist, A.S.; Calverley, P.M.; Jenkins, C.R.; Hurd, S.S. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir. Crit. Care Med. 2001, 163, 1256-1276.
245. Keatings, V.M.; Jatakanon, A.; Worsdell, Y.M.; Barnes, P.J. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am. J. Respir. Crit Care Med. 1997, 155, 542-548.
246. Barnes, N.C.; Qiu, Y.S.; Pavord, I.D.; Parker, D.; Davis, P.A.; Zhu, J.; Johnson, M.; Thomson, N.C.; Jeffery, P.K. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am. J. Respir. Crit Care Med. 2006, 173, 736-743.
247. Kaur, M.; Holden, N.S.; Wilson, S.M.; Sukkar, M.B.; Chung, K.F.; Barnes, P.J.; Newton, R.; Giembycz, M.A. Effect of beta2-adrenoceptor agonists and other cAMP-elevating agents on inflammatory gene expression in human ASM cells: a role for protein kinase A. Am. J. Physiol Lung Cell Mol. Physiol. 2008, 295, L505-L514.
248. Hallsworth, M.P.; Twort, C.H.; Lee, T.H.; Hirst, S.J. beta(2)-adrenoceptor agonists inhibit release of eosinophil-activating cytokines from human airway smooth muscle cells. Br. J. Pharmacol. 2001, 132, 729-741.
249. Shore, S.A.; Moore, P.E. Regulation of beta-adrenergic responses in airway smooth muscle. Respir. Physiol. Neurobiol. 2003, 137, 179-195.
250. Banner, K.H.; Press, N.J. PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease. Br. J. Pharmacol. 2009, 157, 892-906.
251. Gross, N.J.; Giembycz, M.A.; Rennard, S.I. Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor. J. ChronicObstruct. Pulmon. Dis. 2010, 7, 141-153.
252. Giembycz, M.A.; Field, S.K. Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD. Drug Desig. Develop. Therap. 2010, 4, 147-158.
253. Press, N.J.; Banner, K.H. PDE4 inhibitors - a review of the current field. Prog. Med. Chem. 2009, 47, 37-74.
254. Sowa, G. Caveolae, caveolins, cavins, and endothelial cell function: new insights. Front Physiol. 2012, 2, 120.
255. Fish, J.E. A primer on the role of microRNAs in endothelial biology and vascular disease. Semin. Nephrol. 2012, 32, 167-175.
256. Hirase, T.; Noda, K. Endothelial dysfunction as a cellular mechanism for vascular failure. Am. J. Physiol. Heart Circ. Physiol. 2012, 302, H499-H505.
257. Vestweber, D. Novel insights into leukocyte extravasation. Curr. Opin. Hematol. 2012, 19, 212-217.
258. Vestweber, D.; Broermann, A.; Schulte, D. Control of endothelial barrier function by regulating vascular endothelial-cadherin. Curr. Opin. Hematol. 2010, 17, 230-236.
259. Vestweber, D.; Winderlich, M.; Cagna, G.; Nottebaum, A.F. Cell adhesion dynamics at endothelial junctions: VE-cadherin as a major player. Trends Cell Biol. 2009, 19, 8-15.
260. Vestweber, D. Adhesion and signaling molecules that control endothelial cell contacts. Immunol. Rev. 2007, 218, 178-196.
261. Davies, D.E. The role of the epithelium in airway remodeling in asthma. Proc. Am. Thorac. Soc. 2009, 6, 678-682.
262. Niessen, C.M. Tight junctions/adherens junctions: Basic structure and function. J. Investig Dermatol. 2007, 127, 2525-2532.
263. Evans, M.J.; Fanucchi, M.V.; Plopper, C.G.; Hyde, D.M. Postnatal development of the lamina reticularis in primate airways. Anatom. Rec. 2010, 293, 947-954.
264. Evans, M.J.; van Winkle, L.S.; Fanucchi, M.V.; Plopper, C.G. Cellular and molecular characteristics of basal cells in airway epithelium. Experiment. Lung Res. 2001, 27, 401-415.
265. Evans, M.J.; van Winkle, L.S.; Fanucchi, M.V.; Toskala, E.; Luck, E.C.; Sannes, P.L.; Plopper, C.G. Three-dimensional organization of the lamina reticularis in the rat tracheal basement membrane. Am. J. Respir. Cell Mol. Biol. 2000, 22, 393-397.
266. Anderson, J.M.; van Italie, C.M. Physiology and function of the tight junction. ColdSpringHarb. Perspect. Biol. 2009, 1, a002584.
267. Chiba, H.; Osanai, M.; Murata, M.; Kojima, T.; Sawada, N. Transmembrane proteins of tight junctions. Biochim. Biophys. Acta 2008, 1778, 588-600.
268. Terry, S.; Nie, M.; Matter, K.; Balda, M.S. Rho signaling and tight junction functions. Physiology 2010, 25, 16-26.
269. Corada, M.; Chimeti, S.; Cera, M.R.; Vinci, M.; Salio, M.; Fiordaliso, F.; De Angelis, N.; Villa, A.; Bossi, M.; Staszewsky, L.I.; Vecchi, A.; Parazzoli, D.; Motoike, T.; Latini, R.; Dejana, E. Junctional adhesion molecule-A-deficient polymorphonuclear cells show reduced diapedesis in peritonitis and heart ischemia-reperfusion injury. Proc. Natl. Acad. Sci. USA 2005, 102, 10634-10639.
270. Khandoga, A.; Kessler, J.S.; Meissner, H.; Hanschen, M.; Corada, M.; Motoike, T.; Enders, G.; Dejana, E.; Krombach, F. Junctional adhesion moleculae A deficiency increases hepatic ischmiareperfusion injury despite reduction of neutrophil transendothelial migration. Blood 2005, 106, 725-733.
271. Quint, J.K.; Wedzicha, J.A. The neutrophil in chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 2007, 119, 1065-1071.
272. Walters, R.W.; Freimuth, P.; Moninger, T.O.; Ganske, I.; Zabner, J.; Welsh, M.J. Adenovirus fiber disrupts CAR-mediated intercellular adhesion allowing virus escape. Cell 2002, 110, 789-799.
273. Cohen, C.J.; Shieh, J.T.C.; Pickles, R.J.; Okegawa, T.; Hsieh, J.-T.; Bergelson, J.M. The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction. Proc. Natl. Acad. Sci. USA 2001, 98, 15191-15196.
274. Zen, K.; Liu, Y.; McCall, I.C.; Wu, T.; Lee, W.; Babbin, B.A.; Nusrat, A.; Parkos, C.A. Neutrophil migration across tight junctions is mediated by adhesive interactions between epithelial coxsackie and adenovirus receptor and a junctional adhesion molecule-like protein on neutrophils. Mol. Biol. Cell 2005, 16, 2694-2703.
275. Giepsmans, B.N.; Ijzendoorn, S.C. Epithelial cell-cell junctions and plasma membrane domains. Biochim. Biophys. Acta 2009, 1788, 820-831.
276. Hernandez, S.; Chavez Munguia, B.; Gonzalez-Mariscal, L. ZO-2 silencing in epithelial cells perturbs the gate and fence function of tight junctions and leads to an atypical monolayer architecture. Exp. Cell Res. 2007, 313, 1533-1547.
277. Fanning, A.S.; Jameson, B.J.; Jesaitis, L.A.; Anderson, J.M. The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton. J. Biol. Chem. 1998, 273, 29745-29753.
278. González-Mariscal, L.; Tapia, R.; Chamorro, D. Crosstalk of tight junctions components with signaling pathways. Biochim. Biophys. Acta 2008, 1778, 729-756.
279. Guillemot, L.; Paschoud, S.; Pulimeno, P.; Foglia, A.; Citi, S. The cytoplasmic plaque of tight junctions: a scaffolding and signalling center. Biochim. Biophys. Acta 2008, 1778, 601-613.
280. Rodgers, L.S.; Fanning, A.S. Regulation of epithelial permeability by the actin cytoskeleton. Cytoskeleton 2011, 68, 653-660.
281. Fanning, A.S.; Anderson, J.M. Zonula occludens-1 and -2 are cytosolic scaffolds that regulate the assembly of cellular junctions. Ann. N. Y. Acad. Sci. 2009, 1165, 113-120.
282. van Itallie, C.M.; Fanning, A.S.; Bridhges, A.; Anderson, J.M. ZO-1 stabilizes the tight junction solute barrier through coupling to the perijunctional cytoskeleton. Mol. Biol. Cell 2009, 20, 3930-3940.
283. Nawijn, M.C.; Hackett, T.L.; Postma, D.S.; van Oosterhout, A.J.M.; Heijink, I.H. E-cadherin: gatekeeper of airway mucosa and allergic sensitization. Trends Immunol. 2011, 32, 248-255.
284. Lodish, H.; Berk, A.; Zipursky, S.L. Molecular Cell Biology, 4th ed.; W.H. Freeman and Company: New York, NY, USA, 2000.
285. Goeckeler, Z.M.; Wysolmerski, R.B. Myosin phosphatase and cofilin mediate cAMP/cAMP- dependent protein kinase-induced decline in endothelial isometric tension and myosin II regulatory light chain phosphorylation. J. Biol. Chem. 2005, 280, 33083-33095.
286. Pritchard, C.A.; Hayes, L.; Wojnowski, L.; Zimmer, A.; Marais, R.M.; Norman, J.C. B-Raf acts via ROCKII/LIMK/Cofilin pathway to maintain actin stress fibres in fibroblasts. Mol. Cell. Biol. 2004, 24, 5937-5952.
287. De La Cruz, E.M.; Ostap, E.M. Relating biochemistry and function in the myosin superfamily. Curr. Opin. Cell Biol. 2004, 16, 61-67.
288. Pannekoek, W.J.; Kooistra, M.R.; Zwartkruis, F.J.; Bos, J.L. Cell-cell junction formation: The role of Rap1 and Rap1 guanine nucleotide exchange factors. Biochim. Biophys. Acta 2009, 1788, 790-796.
289. Retta, S.F.; Balzac, F.; Avolio, M. Rap1: A turnabout for the crosstalk between cadherins and integrins. Eur. J. Cell Biol. 2006, 85, 283-293.
290. van Straaten, J.F.; Coers, W.; Noordhoek, J.A.; Huitema, S.; Flipsen, J.T.; Kauffman, H.F.; Timens, W.; Postma, D.S. Proteoglycan changes in the extracellular matrix of lung tissue from patients with pulmonary emphysema. Mod. Pathol. 1999, 12, 697-705.
291. Greenlee, K.J.; Werb, Z.; Kheradmand, F. Matrix metalloproteinase in lung: Multiple, multifarious, and multifaceted. Physiol. Rev. 2007, 87, 69-98.
292. Page-McCaw, A.; Ewald, A.J.; Werb, Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat. Rev. Mol. Cell Biol. 2007, 8, 221-233.
293. Parks, W.C.; Wilson, C.L.; López-Boado, Y.S. Matrix metalloproteinases as modulators of inflammtion and innate immunity. Nat. Rev. Immunol. 2004, 4, 617-629.
294. Gueders, M.M.; Foidart, J.M.; Noel, A.; Cataldo, D.D. Matrix met-aletal/et-alloproteinases (MMPs) and tissue inhibitors of MMPs in the respiratory tract: Potential implications in asthma and other lung diseases. Eur. J. Pharmacol. 2006, 533, 133-144.
295. Vadenbroucke, R.E.; Dejonckheere, E.; Libert, C. A therapeutic role for matrix metalloproteinase inhibitors in lung diseases? Eur. Respir. J. 2011, 38, 1200-1214.
296. Demedts, I.K.; Brusselle, G.G.; Bracke, K.R.; Vemaelen, K.Y.; Pauwels, R.A. Matrix metalloproteinases in asthma and COPD. Curr. Opin. Pharmacol. 2005, 5, 257-263.
297. Oikonomid, S.; Kostikas, K.; Tsilioni, I.; Tanou, K.; Gourgoulianis, K.I.; Kiropoulos, T.S. Matrix metalloproteinases in respiratory diseases: from pathogenesis to potential clinical implications. Curr. Med. Chem. 2009, 16, 1214-1228.
298. Vial, W.C. Cigarette smoking and lung disease. Am. J. Med. Sci. 1986, 291, 130-142.
299. Lawrence, D.W.; Comerford, K.M.; Colgan, S.P. Role of VASP in reestablishment of epithelial tight junction assembly after Ca2+ switch. Am. J. Physi. Am. J. Physiol. Cell Physiol. 2002, 282, C1235-C1245.
300. Lorenowicz, M.J.; Fernandez-Borja, M.; van Stalborch, A.M.; van Sterkenburg, M.A.; Hiemstra, P.S.; Hordijk, P.L. Microtubule dynamics and rac-1 signaling independently regulate barrier function in lung epithelial cells. Am. J. Physiol. Lung Cell Mol. Physiol. 2007, 293, L1321-L1331.
301. Baumer, Y.; Drenckhahn, D.; Waschke, J. cAMP induced Rac1-mediated cytoskeletal reorganization in microvascular endothelium. Histochem. Cell Biol. 2008, 129, 765-778.
302. Logue, J.S.; Whiting, J.L.; Tunquist, B.; Langeberg, L.K.; Scott, J.D. Anchored protein kinase A recruitment of active Rac GTPase. J. Biol. Chem. 2011, 286, 22113-22121.
303. Logue, J.S.; Whiting, J.L.; Scott, J.D. Sequestering Rac with PKA confers cAMP control of cytoskeletal remodeling. SmallGTPases 2011, 3, 173-176.
304. Michel, C.C.; Curry, F.E. Microvascular permeability. Physiol. Rev. 1999, 79, 703-761.
305. Metha, D.; Malik, A.B. Signaling mechanisms regulating endothelial permeability. Physiol. Rev. 2006, 86, 279-367.
306. Serezani, C.H.; Ballinger, M.N.; Aronoff, D.M.; Peters-Golden, M. Cyclic AMP: master regulator of innate immune cell function. Am. J. Respir. Cell Mol. Biol. 2008, 39, 127-132.
307. Spindler, V.; Schlegel, N.; Waschke, J. Role of GTPases in control of microvascular permeability. Cardiovasc. Res. 2010, 87, 243-253.
308. Bogatcheva, N.V.; Zemskova, M.A.; Kovalenkov, Y.; Poirier, C.; Verin, A.D. Molecular mechanisms mediating protective effect of cAMP on lipopolysaccharide (LPS)-induced human lung microvascular endothelial (HLMVEC) hyperpermeability. J. Cell. Physiol. 2009, 221, 750-759.
309. van Wetering, S.; van Buul, J.D.; Quik, S.; Mul, F.P.J.; Anthony, E.C.; ten Klosster, J.-P.; Collard, J.G.; Hordijk, P.L. Reactive oxygen species mediate Rac-induced loss of cell-cell adhesion in primary human endothelial cells. J. CellSci. 2002, 115, 1837-1846.
310. Birukova, A.A.; Zagranichnaya, T.; Alekseeva, E.; Bokoch, G.M.; Birukov, K.G. Epac/Rap and PKA are novel mechanisms of ANP-induced Rac-mediated pulmonary endothelial barrier protection. J. Cell Physiol. 2008, 215, 715-724.
311. Birukova, A.A.; Fu, P.; Xing, J.; Birukov, K.G. Rap1 mediates protective effects of iloprost against ventilator-induced lung injury. J. Appl. Physiol. 2009, 107, 1900-1910.
312. Birukova, A.A.; Zagranichnaya, T.; Fu, P.; Alekseeva, E.; Cheng, X.; Jacobson, J.R.; Birukov, K.G. Prostaglandines PGE2 and PGI2 promote endothelial barrier enhancement via PKA- and Epac1/Rap1-dependent Rac activation. Exp. Cell Res. 2007, 313, 2504-2520.
313. Xing, J.; Birukova, A.A. ANP attenuates inflammatory signaling and Rho pathway of lung endothelial permeability induced by LPS and TNFa. Microvascul. Res. 2010, 79, 56-62.
314. Cullere, X.; Shaw, S.K.; Andersson, L.; Hirahashi, J.; Luscinskas, F.W.; Mayadas, T.N. Regulation of vascular endothelial barrier function by Epac, a cAMP-activated exchange factor for Rap GTPase. Blood 2005, 105, 1950-1955.
315. Glading, A.; Han, J.; Stockton, R.A.; Ginsberg, M.H. KRIT-1/CCM1 is a Rap1 effector that regulates endothelial cell cell junctions. J. Cell Biol. 2007, 179, 247-254.
316. Stockton, R.A.; Shenkar, R.; Awad, I.A.; Ginsberg, M.H. Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity. J. Exp. Med. 2010, 4, 881-896.
317. Gao, S.; Li, C.; Shimokawa, T.; Terashita, T.; Matsuda, S.; Yaoita, E.; Kobayashi, N. Rho-family small GTPases are involved in forskolin-induced cell-cell contact formation of renal glomerular podocytes in vitro. Cell Tissue Res. 2007, 328, 391-400.
318. Costantini, T.W.; Deree, J.; Loomis, W.; Putman, J.G.; Choi, S.; Baird, A.; Eliceiri, B.P.; Bansal, V.; Coimbra, R. Phosphodiesterase inhibition attenuates alterations to the tight junction proteins occludin and ZO-1 in immunostimulated caco-2 intestinal monolayers. Life Sci. 2009, 84, 18-22.
319. White, C.D.; Brown, M.D.; Sacks, D.B. IQGAPs in cancer: A family of scaffold proteins underlying tumorigenesis. FEBS Lett. 2009, 583, 1817-1824.
320. Oldenburger, A.; Rijks, W.F.; Sewbalaksing, V.D.; Poppinga, W.J.; Heijink, I.H.; Maarsingh, H.; Schmidt, M. A-kinase anchoring proteins (AKAPs) as potential novel therapeutic targets to improve cigarette smoke-induced loss of epithelial barrier function. Availabe online: http://www.pA2online.org/abstracts/Vol10Issue3abst108P.pdf, accessed on 28 November 2012.